Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 15/07/2024 BST 5-day change 1st Jan Change
2.91 USD +4.30% Intraday chart for Lexaria Bioscience Corp. +12.79% +132.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024 CI
HC Wainwright Initiates Lexaria Bioscience at Buy Rating With $10 Price Target MT
Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2 CI
Lexaria Bioscience Corp. Receives New Patents for Antiviral Drug Delivery and for Treating Epilepsy CI
Lexaria Bioscience Secures New Antiviral Drug Delivery, Epilepsy Patents MT
Lexaria Bioscience Hires Contract Research Organization For 12-week Study MT
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study CI
Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study CI
Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study MT
Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise MT
Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study CI
Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study CI
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs CI
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents CI
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer CI
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating MT
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1 CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1 CI
Chart Lexaria Bioscience Corp.
More charts
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.91 USD
Average target price
10 USD
Spread / Average Target
+243.64%
Consensus
  1. Stock Market
  2. Equities
  3. LEXX Stock
  4. News Lexaria Bioscience Corp.
  5. HC Wainwright Initiates Lexaria Bioscience at Buy Rating With $10 Price Target